ReviewReumatologia2026
Tjalma syndrome in late-onset systemic lupus erythematosus.
Review in Reumatologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tjalma syndrome, also named pseudo-pseudo Meigs syndrome, is a rare complication of serositis in patients with systemic lupus erythematosus (SLE). It is associated with a high level of the ovarian tumor marker CA-125 and pleural effusion and ascites, which can suggest an ovarian tumor (benign or malignant), in patients with SLE. Available literature data include case reports of female patients with SLE ranging in age from 14 to 82. Patients under 50 years of age predominate. Our own experience led us to analyze the observations in this review against the background of our experience with a female patient with late-onset SLE. This review discusses why exploration of paraneoplastic syndrome can delay immunosuppressive therapy for this serious SLE manifestation. The main goal of this case-based review is to compare the clinical and laboratory findings of our patient with those reported in the literature and to raise awareness of this rare entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.